论文部分内容阅读
随着肿瘤发生发展分子机制的不断研究,基因诊断将会越来越多地应用在肺癌的肿瘤标志物上。目前尚未找到肺癌的特异性抗原,国内外研究人员已发现多种有潜力并用于肺癌早期诊断、临床分型和分期、预后判断和疗效观察的肿瘤生物标志。此篇以神经元特异性烯醇化酶、癌胚抗原、细胞角蛋白19片段抗原等基因表型标志以及丝氨酸蛋白酶抑制剂的进化枝B的成员3、微管关联的同源物、脆性组胺酸三联体、DnaJ样热激蛋白40、醛酮还原酶家族1的成员B10等基因标志为例,对肺癌肿瘤标志物的研究进展作一综述。
With the continuous development of molecular mechanisms of tumorigenesis, genetic diagnosis will be more and more used in lung cancer tumor markers. At present, no specific antigens have been found in lung cancer. Researchers both at home and abroad have discovered a variety of tumor biomarkers that have the potential for early diagnosis, clinical classification and staging of lung cancer, prognostic judgment and curative effect observation. This article with neuron-specific enolase, carcinoembryonic antigen, cytokeratin 19 fragment antigen gene phenotypic markers and serine protease inhibitors clade B member 3, microtubule associated homologue, fragile histamine Acid triplet, DnaJ-like heat shock protein 40, aldo-keto reductase family member B10 and other genetic markers as an example, the progress of lung cancer tumor markers are reviewed.